Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.
about
Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced diseaseChemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancerSecond or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced diseaseSupportive care for patients with gastrointestinal cancerChemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trialsTumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives50 Years of progress in the systemic therapy of non-small cell lung cancerOverexpression of deubiquitinating enzyme USP28 promoted non-small cell lung cancer growthPaclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.Increasing dose intensity of cisplatin-etoposide in advanced nonsmall cell lung carcinoma: a phase III randomized trial of the Spanish Lung Cancer Group.Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: results of an Argentinean multicentre phase II trial.A phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced nonsmall cell lung carcinoma.Comparison of vinorelbine-Cisplatin with gemcitabine-Cisplatin in patients with advanced non-small cell lung cancer.A pilot study of mitomycin, cisplatin and continuous infusion 5-fluorouracil (MCF) in advanced non-small-cell lung cancerPhase II study of nitrosourea fotemustine as single-drug chemotherapy in poor-prognosis non-small-cell lung cancerThe treatment of metastatic non-small cell lung cancer in the elderly: an evidence-based approachChemotherapy for non-small cell lung cancer.A comparison of a new multinomial stopping rule with stopping rules of fleming and gehan in single arm phase II cancer clinical trials.Novel combination chemotherapy in the treatment of non-small cell lung cancer.Management of non-small cell lung cancer with oligometastasisSecond-line chemotherapy for non-small cell lung cancer.Patients' perspectives on palliative chemotherapy of colorectal and non--colorectal cancer: a prospective study in a chemotherapy- experienced populationChallenges in Implementing Personalized Medicine for Lung Cancer within a National Healthcare SystemChemotherapy plus best supportive care versus best supportive care in patients with non-small cell lung cancer: a meta-analysis of randomized controlled trialsPlacebo effects in oncology.Advanced non-small cell lung cancer: the role of maintenance therapyLung cancer. 4: chemotherapy for non-small cell lung cancer: the end of the beginning.Pemetrexed and its emerging role in the treatment of thoracic malignancies.Lung cancer 7: management of lung cancer in elderly patients.Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer.Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancerVideo-assisted thoracoscopic surgery is more favorable than thoracotomy for administration of adjuvant chemotherapy after lobectomy for non-small cell lung cancerPrognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients: Patient Characteristics and Type of Chemotherapy.LKB1 deficiency enhances sensitivity to energetic stress induced by erlotinib treatment in non-small-cell lung cancer (NSCLC) cells.Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study.Clinical evaluation of serum tumour marker CA 242 in non-small cell lung cancer.A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer.A phase II study of high dose epirubicin in unresectable non small cell lung cancerEpidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based AnalysisSymptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer
P2860
Q24200518-E7BF46B0-D43B-46F7-A001-06C8CD47E50EQ24235422-9DAD055A-7757-4C49-A81F-9EC2415AED49Q24243664-822E186F-318C-43F2-8888-EECFEC36186EQ24246675-D90D7FB8-7FFB-4DD7-BB3C-3753A709A6E9Q24643017-BD4DA52C-C154-4F06-9AC6-C18075DE88CFQ27014117-FB65B94B-3301-4371-BCF8-9B8EAF283153Q27014978-466E5528-D5F8-4ACD-944E-A9FC4A6E51A3Q28391713-4329D085-9F4F-4AD7-8456-C39C03E06E0FQ31791219-64F13C8F-8C12-4980-AC6B-8B5EC97945AAQ33328264-596773EE-0A3C-480A-8C73-A3A3C373DC0CQ33330549-F0BFAAC0-EB1C-49D0-8B70-BF7FF054BB7EQ33344553-63375A5D-1F57-4C85-A229-20EB6490F099Q33393287-AD0AD7D6-0563-42CB-9BEA-F78C3E100460Q33489857-289E88F9-4536-467D-BA4D-E820AD1AC11FQ33492796-FDA7E861-2ED0-4F04-BA0C-0531C78F4535Q33878770-5B8F442F-3187-46B4-A743-13EA0FAD3BD6Q33910132-95A7525C-F7C1-4E14-9748-385AFDE9830DQ33938637-C234ED53-760C-4210-8EFD-40B171F8E47BQ34181910-3F037CFA-583C-4E18-8570-62B45AC962DFQ34246641-48C9693F-D635-4726-AC2A-6B3588E62334Q34424790-07A7AB1F-A029-477E-A446-BEE6D558750CQ34580422-0C285CEA-BA1D-494A-94D1-D6DEABCFBCE0Q34608597-722B16E8-D150-4029-B6B0-EEABF8DC0090Q34650404-6E94CDF1-DC6D-4A30-B943-91ABCC23EE7BQ35037527-FDAE3857-7F29-4E38-A879-8A222B5223DDQ35076224-BD8B02CA-C537-4FEA-84F4-DDADD722A3E1Q35096015-9004E17A-1D69-40DA-90C0-67469EC0AF13Q35117095-0C31FA9B-DC5D-4B82-A8CA-E7DE593F0D44Q35186819-07C1E3E2-5346-480B-B67B-329F820A4ED7Q35233464-341E365C-C4B9-4EEE-BBEC-77ACDE338DB5Q35591358-405DD2C4-3F0F-4913-800B-2C13C65B3866Q35674874-53EA3828-4BD9-4A1E-B104-E591B3A5EB28Q35763231-C963558C-1345-4C4E-9367-804D8E35439EQ35801173-CA05811F-11C4-4E72-928B-58361E498570Q35976932-40F862BC-EFB9-4BEC-956C-EF6886A5762AQ35976947-0B619022-1E71-4035-96DA-35504C70E900Q35981666-0F0CBAA1-9776-4EB9-9695-7B67900AAEFEQ35993654-B1E04186-B076-4745-BE87-4AFA8FF0799FQ36040002-EC42E962-5E0E-46E8-9188-3B2470C6D6EAQ36080357-3D0EFF5F-FAE5-4780-9B72-81EB51FD253D
P2860
Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年学术文章
@wuu
1988年学术文章
@zh-cn
1988年学术文章
@zh-hans
1988年学术文章
@zh-my
1988年学术文章
@zh-sg
1988年學術文章
@yue
1988年學術文章
@zh
1988年學術文章
@zh-hant
name
Chemotherapy can prolong survi ...... multicenter randomized trial.
@en
Chemotherapy can prolong survi ...... multicenter randomized trial.
@nl
type
label
Chemotherapy can prolong survi ...... multicenter randomized trial.
@en
Chemotherapy can prolong survi ...... multicenter randomized trial.
@nl
prefLabel
Chemotherapy can prolong survi ...... multicenter randomized trial.
@en
Chemotherapy can prolong survi ...... multicenter randomized trial.
@nl
P2093
P356
P1476
Chemotherapy can prolong survi ...... multicenter randomized trial.
@en
P2093
A M Arnold
D I Hodson
P304
P356
10.1200/JCO.1988.6.4.633
P407
P577
1988-04-01T00:00:00Z